{"id":"https://openalex.org/W2767201644","doi":"https://doi.org/10.1007/s40262-017-0605-6","title":"Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials","display_name":"Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials","alternate_titles":[],"publication_year":2017,"publication_date":"2017-10-26","ids":{"openalex":"https://openalex.org/W2767201644","doi":"https://doi.org/10.1007/s40262-017-0605-6","mag":"2767201644","pmid":"https://pubmed.ncbi.nlm.nih.gov/29076110","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6028884"},"language":"en","primary_location":{"id":"doi:10.1007/s40262-017-0605-6","doi":"https://doi.org/10.1007/s40262-017-0605-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-017-0605-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-017-0605-6.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2767201644"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40262-017-0605-6.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069999293","display_name":"Ben Kl\u00fcnder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128201","display_name":"AbbVie (Germany)","ror":"https://ror.org/03538jp08","country_code":"DE","type":"company","lineage":["https://openalex.org/I2948539688","https://openalex.org/I4210128201"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ben Kl\u00fcnder","raw_affiliation_strings":["AbbVie Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany","institution_ids":["https://openalex.org/I4210128201"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021804383","display_name":"Mohamed\u2010Eslam F. Mohamed","orcid":"https://orcid.org/0000-0003-0959-2025","observed_orcids":["https://orcid.org/0000-0003-0959-2025"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mohamed-Eslam F. Mohamed","raw_affiliation_strings":["AbbVie Clinical Pharmacology and Pharmacometrics, AbbVie, 1 North Waukegan Road, Bldg. AP31-3, North Chicago, IL, 60064, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Clinical Pharmacology and Pharmacometrics, AbbVie, 1 North Waukegan Road, Bldg. AP31-3, North Chicago, IL, 60064, USA","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5047096414","display_name":"Mohamed I. A. Othman","orcid":"https://orcid.org/0000-0002-0405-8918","observed_orcids":["https://orcid.org/0000-0002-0405-8918"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Ahmed A. Othman","raw_affiliation_strings":["AbbVie Clinical Pharmacology and Pharmacometrics, AbbVie, 1 North Waukegan Road, Bldg. AP31-3, North Chicago, IL, 60064, USA. ahmed.othman@abbvie.com","AbbVie Clinical Pharmacology and Pharmacometrics, AbbVie, 1 North Waukegan Road, Bldg. AP31-3, North Chicago, IL, 60064, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Clinical Pharmacology and Pharmacometrics, AbbVie, 1 North Waukegan Road, Bldg. AP31-3, North Chicago, IL, 60064, USA. ahmed.othman@abbvie.com","institution_ids":["https://openalex.org/I2948539688"]},{"raw_affiliation_string":"AbbVie Clinical Pharmacology and Pharmacometrics, AbbVie, 1 North Waukegan Road, Bldg. AP31-3, North Chicago, IL, 60064, USA","institution_ids":["https://openalex.org/I2948539688"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5047096414"],"corresponding_institution_ids":["https://openalex.org/I2948539688"],"apc_list":{"value":4990,"currency":"USD","value_usd":4990},"apc_paid":{"value":4990,"currency":"USD","value_usd":4990},"fwci":8.1818,"has_fulltext":true,"cited_by_count":82,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.98517898,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"57","issue":"8","first_page":"977","last_page":"988"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.7910000085830688,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.7910000085830688,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.1340000033378601,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.022299999371170998,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/upadacitinib","display_name":"upadacitinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/population-pharmacokinetics","display_name":"population pharmacokinetics","score":0.9380000233650208},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9980000257492065},{"id":"https://openalex.org/keywords/jak1-inhibitor","display_name":"JAK1 inhibitor","score":0.8029999732971191},{"id":"https://openalex.org/keywords/renal-dysfunction","display_name":"renal dysfunction","score":0.6940000057220459},{"id":"https://openalex.org/keywords/sex-differences","display_name":"sex differences","score":0.8040000200271606},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.7459999918937683},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.6129999756813049},{"id":"https://openalex.org/keywords/oral-clearance","display_name":"oral clearance","score":0.48100000619888306},{"id":"https://openalex.org/keywords/volume-of-distribution","display_name":"volume of distribution","score":0.7649999856948853},{"id":"https://openalex.org/keywords/absorption-lag-time","display_name":"absorption lag time","score":0.578000009059906},{"id":"https://openalex.org/keywords/mean-absorption-time","display_name":"mean absorption time","score":0.8379999995231628},{"id":"https://openalex.org/keywords/nonlinear-mixed-effects-modelling","display_name":"nonlinear mixed-effects modelling","score":0.7099999785423279}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7849314212799072},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6853395700454712},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.6520012617111206},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5573889017105103},{"id":"https://openalex.org/C159641895","wikidata":"https://www.wikidata.org/wiki/Q108377937","display_name":"Renal function","level":2,"score":0.5501068234443665},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.5001006126403809},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4501502513885498},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.41888657212257385},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39734840393066406},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3300541639328003},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1007/s40262-017-0605-6","doi":"https://doi.org/10.1007/s40262-017-0605-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-017-0605-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-017-0605-6.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5008718","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6028884","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6028884","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6028884/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacokinet","raw_type":"Text"},{"id":"pmid:29076110","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29076110","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacokinetics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1007/s40262-017-0605-6","doi":"https://doi.org/10.1007/s40262-017-0605-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-017-0605-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-017-0605-6.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320309117","display_name":"AbbVie","ror":"https://ror.org/02g5p4n58"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2767201644.pdf","grobid_xml":"https://content.openalex.org/works/W2767201644.grobid-xml"},"referenced_works_count":16,"referenced_works":["https://openalex.org/W105671925","https://openalex.org/W1880040018","https://openalex.org/W2042553471","https://openalex.org/W2063974195","https://openalex.org/W2072026013","https://openalex.org/W2074438676","https://openalex.org/W2090629053","https://openalex.org/W2096906176","https://openalex.org/W2145434855","https://openalex.org/W2165902578","https://openalex.org/W2415732068","https://openalex.org/W2509054882","https://openalex.org/W2559407770","https://openalex.org/W2559743688","https://openalex.org/W2615504593","https://openalex.org/W3199172499"],"related_works":["https://openalex.org/W2931411148","https://openalex.org/W2987055356","https://openalex.org/W2950751432","https://openalex.org/W2899925797","https://openalex.org/W2910247357","https://openalex.org/W2952693527","https://openalex.org/W2995813398","https://openalex.org/W2802794771","https://openalex.org/W2909764814","https://openalex.org/W2951154958"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1],"OBJECTIVES:":[2],"Upadacitinib":[3,45,205,214],"is":[4,225],"a":[5,139,147],"janus":[6],"kinase":[7],"(JAK)":[8],"1":[9],"inhibitor":[10],"being":[11],"developed":[12],"for":[13,108,138,161,167,238],"the":[14,37,155],"treatment":[15],"of":[16,39,114],"rheumatoid":[17],"arthritis":[18],"(RA)":[19],"and":[20,33,36,55,63,88,98,119,133,149,166,190,270],"other":[21,145,239],"inflammatory":[22],"diseases.":[23],"This":[24],"work":[25],"characterized":[26],"upadacitinib":[27,42,101,109,152,193,223,259],"population":[28],"pharmacokinetics":[29,215],"in":[30,227,232],"healthy":[31,53,141,173,233],"subjects":[32,54,168,198,228],"RA":[34,57,66,170,178,200,230],"patients":[35,58],"effects":[38,257],"covariates":[40,243],"on":[41,144,258],"exposure.":[43,260],"METHODS:":[44],"plasma":[46],"concentrations":[47],"(n":[48],"=":[49],"6399)":[50],"from":[51,59],"107":[52],"466":[56],"three":[60],"phase":[61,67],"I":[62],"two":[64],"12-week":[65],"IIb":[68],"trials":[69],"(1-48":[70],"mg":[71],"immediate-release":[72],"doses":[73],"across":[74],"studies)":[75],"were":[76,84,123,185],"analyzed":[77],"using":[78,86],"non-linear":[79],"mixed-effects":[80],"modeling.":[81],"The":[82],"models":[83],"qualified":[85],"bootstrap":[87,105],"stochastic":[89],"simulations.":[90],"RESULTS:":[91],"A":[92,220],"two-compartment":[93],"model":[94],"with":[95,169,177,179,197,199,201,210,229,236,254],"first-order":[96],"absorption":[97,116,121],"elimination":[99],"described":[100],"pharmacokinetics.":[102],"Estimates":[103],"(95%":[104],"confidence":[106],"interval)":[107],"oral":[110],"clearance,":[111],"steady-state":[112],"volume":[113],"distribution,":[115],"lag":[117],"time,":[118],"mean":[120],"time":[122],"39.7":[124],"(37.8-41.5)":[125],"L/h,":[126],"210":[127],"(196-231)":[128],"L,":[129],"0.48":[130],"(0.47-0.49)":[131],"h,":[132,136],"0.08":[134],"(0.04-0.12)":[135],"respectively,":[137,195],"typical":[140],"male.":[142],"Matching":[143],"covariates,":[146],"16":[148,189],"32%":[150,191],"higher":[151,192],"area":[153],"under":[154],"concentration-time":[156],"curve":[157],"(AUC)":[158],"was":[159,207],"estimated":[160,186,226],"females":[162],"relative":[163,171],"to":[164,172,187],"males,":[165],"volunteers,":[174,234],"respectively.":[175],"Subjects":[176],"mild":[180,246],"or":[181,247],"moderate":[182,248],"renal":[183,203,249],"impairment":[184],"have":[188],"AUC,":[194],"compared":[196],"normal":[202],"function.":[204],"clearance":[206,224],"not":[208,252],"correlated":[209],"body":[211],"weight.":[212],"CONCLUSIONS:":[213],"follow":[216],"dose-proportional,":[217],"bi-exponential":[218],"disposition.":[219],"slightly":[221],"lower":[222],"than":[231],"consistent":[235],"observations":[237],"JAK":[240],"inhibitors.":[241],"Other":[242],"(weight,":[244],"sex,":[245],"impairment)":[250],"are":[251],"associated":[253],"clinically":[255],"relevant":[256],"TRIAL":[261],"REGISTRATION:":[262],"ClinicalTrials.gov":[263],"(":[264],"https://clinicaltrials.gov/":[265],")":[266],"identifiers:":[267],"NCT01741493,":[268],"NCT02066389,":[269],"NCT01960855.":[271]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2767201644","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":13},{"year":2019,"cited_by_count":20},{"year":2018,"cited_by_count":10}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2017-11-10T00:00:00"}
